The SISAQOL-IMI consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), just announced the publication of its pivotal paper in The ...
Cervical cancer, which affects the reproductive tract, is one of the most common cancers in women worldwide. It is primarily caused by human papillomavirus (HPV), a viral infection that spreads ...
Pre-clinical data for IO Biotech’s next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the ...
Computational tool improves recombinant virus design efficiency and yield. This innovative in-house development is a key component of Transgene’s INTV 1 platform. Poster to be presented at ESMO-AI ...
The "CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026" report has been added to ResearchAndMarkets.com's offering.
Nanoparticle vaccine (or nanovaccine) holds considerable promise for the treatment of cancer. Herein, we defined biochemical mechanisms for a cooperative strategy combining stimuli-responsive ...
Moderna surged on reports of talks with a large biopharma for a potential partnership or buyout, despite trading at multi-year lows. MRNA's promising cancer vaccine data and surprising findings on ...
The mRNA COVID-19 vaccines might make some cancer treatments more effective. Lung cancer patients who received the vaccine within a few months of immunotherapy, which revs up the immune system, lived ...
A small group of women with advanced breast cancer received a vaccine via a clinical trial more than 20 years ago. Today, they're all still alive. Scientists say that kind of long-term survival is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback